{"id":823,"date":"2026-10-20T03:13:25","date_gmt":"2026-10-20T01:13:25","guid":{"rendered":"http:\/\/novameds.local\/fr\/?post_type=product&#038;p=823"},"modified":"2026-10-20T04:00:02","modified_gmt":"2026-10-20T02:00:02","slug":"catalog-sunifiram-powder-10-grams","status":"publish","type":"product","link":"https:\/\/novameds.health\/fr\/produit\/catalog-sunifiram-powder-10-grams\/","title":{"rendered":"Sunifiram \u2013 powder, 10 grams"},"content":{"rendered":"<section id=\"composition\" data-nav=\"Composition et d\u00e9tails du produit\">\n<h2>Composition et d\u00e9tails du produit<\/h2>\n<div class=\"nm-catalog-document\">\n<div>\n<h2>Pr\u00e9sentation<\/h2>\n<div>\n<p>Sunifiram (DM-235) is a synthetic pyrrolidinone-derived compound structurally distinct from the classical racetam family despite sharing a related core scaffold, investigated for proposed positive allosteric modulation of AMPA-type glutamate receptors. Research interest centers on its reported high in vitro potency relative to piracetam-class compounds at substantially lower concentrations.<\/p>\n<p>Research applications include AMPA receptor potentiator pharmacology, glutamatergic signalling research, and structure-activity comparison within the pyrrolidinone-derivative compound series.<\/p>\n<ul>\n<li> <span><b>High Purity<\/b> \u2013 99% Purity Guaranteed<\/span><\/li>\n<li> Independently Lab Tested<\/li>\n<li> Research Grade Quality<\/li>\n<li> For Laboratory Research Use Only<\/li>\n<\/ul><\/div>\n<div>\n<p><a href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/4223812\" target=\"_blank\" rel=\"noopener noreferrer\">Donn\u00e9es mol\u00e9culaires sur PubChem<\/a><\/p>\n<\/p><\/div>\n<\/p><\/div>\n<div>\n<h2>Propri\u00e9t\u00e9s<\/h2>\n<div class=\"nm-catalog-table\" tabindex=\"0\" role=\"region\" aria-label=\"Product data\">\n<table>\n<tbody>\n<tr>\n<th>Chemical Formula<\/th>\n<td>C14H18N2O2<\/td>\n<\/tr>\n<tr>\n<th>Synonyms<\/th>\n<td>DM-235<\/td>\n<\/tr>\n<tr>\n<th>Molar Mass<\/th>\n<td>246.304 g\/mol<\/td>\n<\/tr>\n<tr>\n<th>CAS Number<\/th>\n<td>314728-85-3<\/td>\n<\/tr>\n<tr>\n<th>PubChem CID<\/th>\n<td>4223812<\/td>\n<\/tr>\n<tr>\n<th>Total Compound Content<\/th>\n<td>10 grams<\/td>\n<\/tr>\n<tr>\n<th>Shelf Life<\/th>\n<td>36 months<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div><\/div>\n<div>\n<h2>Recherche<\/h2>\n<p>\t\t\t\t\t<span>Sunifiram is studied as a positive allosteric modulator candidate at AMPA-type ionotropic glutamate receptors, a mechanism investigated using patch-clamp electrophysiology to characterise changes in AMPA receptor-mediated current amplitude and desensitization kinetics in the presence of the compound. Comparative potency studies position sunifiram within structure-activity relationship research examining how its specific pyrrolidinone-derived substituent pattern relates to reported nanomolar-range activity, in contrast to the typically higher concentrations required for classical racetam-family compounds in similar assay systems. Independently third-party HPLC-tested; COA available per batch.<\/span>\t\t\t\t\t<\/div>\n<div>\n<h2>FAQ<\/h2>\n<div>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>How does sunifiram&rsquo;s structure relate to and differ from the classical racetam compound family?<\/span><\/p>\n<\/summary>\n<div>\n<p>Sunifiram shares a pyrrolidinone-derived structural lineage conceptually related to the racetam family but is synthesized via a distinct chemical route and carries substituents not present in piracetam, oxiracetam, or other classical racetam-family compounds. This structural distinction is the basis for research comparing sunifiram&rsquo;s receptor-binding and functional potency profile against established racetam compounds, particularly given reports of substantially different potency ranges between the two groups in similar assay systems.<\/p>\n<\/div>\n<\/details>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>What electrophysiological methods characterize sunifiram&rsquo;s proposed AMPA receptor potentiating activity?<\/span><\/p>\n<\/summary>\n<div>\n<p>Patch-clamp electrophysiology in cultured neurons, brain slice preparations, or heterologous expression systems is the standard method for characterising sunifiram&rsquo;s effects on AMPA receptor-mediated currents, with key readouts including peak current amplitude, desensitization rate, and deactivation kinetics in the presence versus absence of the compound. These functional measurements are used alongside receptor-binding assays to determine whether sunifiram acts at an allosteric site distinct from the glutamate orthosteric binding site, consistent with a positive allosteric modulator mechanism.<\/p>\n<\/div>\n<\/details>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>What concentration ranges are typically used in research characterizing sunifiram&rsquo;s in vitro potency?<\/span><\/p>\n<\/summary>\n<div>\n<p>Reports of sunifiram&rsquo;s in vitro activity describe substantially lower effective concentrations than those required for classical racetam-family compounds in comparable assay systems, prompting researchers to use nanomolar-to-low-micromolar concentration ranges when establishing dose-response curves for sunifiram, in contrast to the micromolar-to-millimolar ranges typically required for piracetam-class compounds. Researchers should empirically establish the relevant concentration range for their specific assay system and cell model rather than assuming direct potency transfer from other reported studies.<\/p>\n<\/div>\n<\/details><\/div>\n<\/p><\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>Sunifiram (DM-235) is a synthetic pyrrolidinone-derived compound structurally distinct from the classical racetam family despite sharing a related core scaffold, investigated for proposed positive allosteric modulation of AMPA-type glutamate receptors.<\/p>\n<p>Conditionnement: Sunifiram \u2013 powder, 10 grams.<\/p>\n<p class=\"nm-research-disclaimer\">R\u00e9serv\u00e9 \u00e0 la recherche en laboratoire. Ne pas utiliser chez l\u2019\u00eatre humain ou l\u2019animal.<\/p>\n<p class=\"nm-catalog-image-note\"><small>Conditionnement illustratif g\u00e9n\u00e9r\u00e9 par IA.<\/small><\/p>\n","protected":false},"featured_media":1009,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[24],"product_tag":[],"nm_classification":[],"class_list":["post-823","product","type-product","status-publish","has-post-thumbnail","product_cat-cognitive-health-nootropics","first","instock","shipping-taxable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/novameds.health\/fr\/wp-json\/wp\/v2\/product\/823","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/novameds.health\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/novameds.health\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/novameds.health\/fr\/wp-json\/wp\/v2\/comments?post=823"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/novameds.health\/fr\/wp-json\/wp\/v2\/media\/1009"}],"wp:attachment":[{"href":"https:\/\/novameds.health\/fr\/wp-json\/wp\/v2\/media?parent=823"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/novameds.health\/fr\/wp-json\/wp\/v2\/product_brand?post=823"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/novameds.health\/fr\/wp-json\/wp\/v2\/product_cat?post=823"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/novameds.health\/fr\/wp-json\/wp\/v2\/product_tag?post=823"},{"taxonomy":"nm_classification","embeddable":true,"href":"https:\/\/novameds.health\/fr\/wp-json\/wp\/v2\/nm_classification?post=823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}